Skip to main content
Equibles
ABSI logo

ABSI · Absci Corp · Earnings Call Transcripts & Audio

Track ABSI — free

Use ABSI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABSI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.77 +0.63 (+6.21%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$1.64B
Shares
171.61M
Volume · Sep 30 5.43M Avg daily vol (3M) 3.49M

Absci Corp Earnings Call Transcripts

Quarterly earnings calls for Absci Corp (ABSI), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲53.9% $2.37M −$27.26M '22 Q3 22-11-09 ▲7.2% $1.56M −$19.47M '22 Q4 23-03-30 ▲54.9% $1.27M −$23.36M '23 Q1 23-05-15 ▲236% $3.37M −$41.67M '23 Q2 23-08-14 ▼68.6% $744,000 −$21.99M '23 Q3 23-11-14 ▼78.3% $338,000 −$23.55M '23 Q4 24-03-21 ▼29.2% $898,000 −$21.98M '24 Q1 24-05-14 ▼62.3% $1.27M −$24.75M '24 Q2 24-08-14 ▲128.6% $1.70M −$27.40M '24 Q3 24-11-12 ▲96.7% $665,000 −$28.98M '24 Q4 25-03-18 ▲31.3% $1.18M −$26.35M '25 Q1 25-05-13 ▼53.3% $593,000 −$30.57M '25 Q2 25-08-12 ▼77.8% $378,000 −$28.71M '25 Q3 25-12-11 ▼2.3% $650,000 −$29.56M '25 Q4 26-03-24 ▼81.8% $215,000 −$29.60M '26 Q1 26-05-07 LATEST ▼46.4% $318,000 −$33.21M '26 Q2 26-08-11
Conference
Investor event
2026-09-16
Absci Corp (ABSI) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Absci Corp (ABSI) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-11
Absci Corp (ABSI) Q2 2026 Earnings Call Transcript
Confident tone ABS-201 Phase 1 interim data and PK profile ABS-21 endometriosis program Competitive landscape and standard of care
Revenue
$318,000
▼ 46.4% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Absci Corp (ABSI) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Absci Corp (ABSI) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Absci Corp (ABSI) Q1 2026 Earnings Call Transcript
Confident tone ABS-201 androgenic alopecia (AGA) program Pipeline expansion - prolactin / ABS-202 Endometriosis indication
Revenue
$215,000
▼ 81.8% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Absci Corp (ABSI) Q4 2025 Earnings Call Transcript
Confident tone ABS-201 clinical progress Androgenetic alopecia (AGA) opportunity R&D efficiency
Revenue
$650,000*
▼ 2.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-12-11
Absci Corp (ABSI) Q3 2025 Earnings Call Transcript
Confident tone ABS-101 phase one interim results and partnership decision Pipeline reprioritization and capital discipline ABS-301 immuno-oncology and other partnered programs
Revenue
$378,000
▼ 77.8% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Absci Corp (ABSI) Q2 2025 Earnings Call Transcript
Confident tone ABS-101 anti-TL1A clinical progress ABS-201 androgenetic alopecia program Almirall collaboration expansion
Revenue
$593,000
▼ 53.3% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Absci Corp (ABSI) Q1 2025 Earnings Call Transcript
Confident tone ABS-101 TL1A Clinical Milestone ABS-201 Androgenic Alopecia Program Business Development and Partnerships
Revenue
$1.18M
▲ 31.3% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Absci Corp (ABSI) Q4 2024 Earnings Call Transcript
Confident tone ABS-101 anti-TL1A program ABS-201 anti-prolactin receptor / androgenic alopecia Pipeline and partner ecosystem growth
Revenue
$665,000*
▲ 96.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Absci Corp (ABSI) Q3 2024 Earnings Call Transcript
Confident tone ABS-201 Dermatology Program ABS-101 TL1A Program R&D Day Catalyst
Revenue
$1.70M
▲ 128.6% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Absci Corp (ABSI) Q2 2024 Earnings Call Transcript
Confident tone New MSK Partnership ABS-101 Anti-TL1A Program Partnership Pipeline / Business Development
Revenue
$1.27M
▼ 62.3% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Absci Corp (ABSI) Q1 2024 Earnings Call Transcript
Confident tone Platform efficiency and cost advantage Internal pipeline progress Partnerships and business development
Revenue
$898,000
▼ 29.2% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Absci Corp (ABSI) Q4 2023 Earnings Call
Revenue
$338,000*
▼ 78.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Absci Corp (ABSI) Q3 2023 Earnings Call
Revenue
$744,000
▼ 68.6% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Absci Corp (ABSI) Q2 2023 Earnings Call
Revenue
$3.37M
▲ 236% YoY
Diluted EPS
$-0.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Absci Corp (ABSI) Q1 2023 Earnings Call
Revenue
$1.27M
▲ 54.9% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Absci Corp (ABSI) Q4 2022 Earnings Call
Revenue
$1.56M*
▲ 7.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Absci Corp (ABSI) Q3 2022 Earnings Call
Revenue
$2.37M
▲ 53.9% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Absci Corp (ABSI) Q2 2022 Earnings Call
Revenue
$1.00M
▲ 37.6% YoY
Diluted EPS
$-0.32
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Absci Corp (ABSI) Q1 2022 Earnings Call
Revenue
$819,000
▼ 23% YoY
Diluted EPS
$-0.33
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Absci Corp (ABSI) Q4 2021 Earnings Call
Revenue
$1.45M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Absci Corp (ABSI) Q3 2021 Earnings Call Transcript
Revenue
$1.54M
▲ 68% YoY
Diluted EPS
$-0.33
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1672688 CUSIP 00091E109 13F (30d) 6 filings 6 filers Visit website Investor relations